Endogenous interleukin‐6 amplifies interleukin‐17 production and corticoid‐resistance in peripheral T cells from patients with multiple sclerosis

Interleukin‐6 (IL‐6) has been implicated in the induction of pathogenic IL‐17‐producing T cells in autoimmune diseases, and studies evaluating the role of this cytokine in T‐cell function in patients with multiple sclerosis (MS) are lacking. Our objective was to evaluate the role of IL‐6 receptor (IL‐6R) signalling on in vitro functional status of T cells from patients with relapsing–remitting MS during clinical remission. Our results demonstrated that, even during the remission phase, activated T cells from patients produce higher levels of IL‐17, and this cytokine was positively correlated with disease severity, as determined by Expanded Disability Status Scale score. In the MS group, the blockade of IL‐6R signalling by anti‐IL‐6R monoclonal antibody reduced IL‐17 production and elevated IL‐10 release by activated CD4⁺ T cells, but it did not alter the production of these cytokines by activated CD8⁺ T cells. Blockade of IL‐6R signalling also reduced the ability of monocytes to up‐regulate T helper type 17 phenotype in patients with MS. Finally, both cell proliferation and IL‐17 release by CD4⁺ and, mainly, CD8⁺ T cells from patients with MS were less sensitive to hydrocortisone inhibition than control group. Interestingly, IL‐6R signalling blockade restored the ability of hydrocortisone to inhibit both T‐cell proliferation and IL‐17 production. Collectively, these results suggest that IL‐6 might be involved in MS pathogenesis by enhancing IL‐17 production and reducing corticoid inhibitory effects on activated T cells.     

IL—6诱导人骨髓瘤细胞表达CD45

目的：研究髓瘤细胞系Sko-007中IL－6信号途径活化与CD45诱导表达之间的关系。方法：首先采用凝胶阻滞电泳（electrophoretic mobility shift assay,EMSA)方法检测参与IL－6信号转导功能的转录因子STAT3和NF－IL－6在Sko-007细胞中的诱导活化情况并确定该细胞中IL－6信号转导途径;进而采用RT－PCR和FACS方法检测CD45mRNA和蛋白在IL－6刺激作用下的诱导表达情况;最后采用以上两种方法观察CD45诱导表达与I－6信号途径活化之间的关系。结果：①两种主要的IL－6信号转导途径JAK／STAT和Ras/NF-IL-6都能够在Sko-007细胞中诱导激活;②CD45mRNA和蛋白的表达量在IL－6刺激作用下明显增加;③STAT3反义表达质粒导入Sko-007细胞后JAK／STAT途径活化信号减弱,同时CD45mRNA诱导表达量下降。结论：Sko－007细胞中JAK／STAT途径的诱导激活介导了CD45的诱导表达。     

Association study of interleukin‐1 family and interleukin‐6 gene single nucleotide polymorphisms in recurrent aphthous stomatitis

Recurrent aphthous stomatitis (RAS) is a common painful, ulcerative oral inflammatory disorder with unknown aetiology. Immune system and aberrant cytokine cascade deemed to be critical in outbreaks of RAS ulcers. Interleukin‐1 (IL‐1) and IL‐6 are the most potent pro‐inflammatory cytokines. Single nucleotide polymorphisms (SNPs) of IL‐1 and IL‐6 genes can affect the secretion of these cytokines. The aim of this study was to investigate the association between RAS and IL‐6 and IL‐1 in Iranian subjects with minor RAS. Genomic DNA was obtained from 64 Iranian patients with RAS. IL‐1α C ?889 T, IL‐1β C ?511 T, IL‐1β C +3962 T, IL‐1R C pst‐I 1970 T, IL‐1Ra C Mspa‐I11100 T, IL‐6 C ?174 G and IL‐6 A nt +565 G polymorphisms were determined using polymerase chain reaction with sequence‐specific primers (PCR‐SSP). The frequency of C ?174 C genotype in the patients group was significantly different from the healthy control. No other significant differences were found in genotype and alleles frequencies between the two groups. These results indicate that certain SNPs of IL‐6 gene at position ?174 which located in promoter have association with predisposition of individuals to RAS.     

Different interleukin‐17‐secreting Toll‐like receptor+ T‐cell subsets are associated with disease activity in multiple sclerosis

Signalling through Toll‐like receptors (TLRs) may play a role in the pathogenesis of autoimmune diseases, such as multiple sclerosis (MS). In the present study, the expression of TLR‐2, ‐4 and ‐9 was significantly higher on CD4⁺ and CD8⁺ T‐cells from MS patients compared to healthy individuals. Following in‐vitro activation, the proportion of interleukin (IL)‐17⁺ and IL‐6⁺ CD4⁺ and CD8⁺ T‐cells was higher in the patients. In addition, the proportion of IFN‐γ‐secreting TLR⁺ CD8⁺ T‐cells was increased in MS patients. Among different IL‐17⁺ T‐cell phenotypes, the proportion of IL‐17⁺ TLR⁺ CD4⁺ and CD8⁺ T‐cells producing IFN‐γ or IL‐6 were positively associated with the number of active brain lesions and neurological disabilities. Interestingly, activation of purified CD4⁺ and CD8⁺ T‐cells with ligands for TLR‐2 (Pam3Csk4), TLR‐4 [lipopolysaccharide (LPS)] and TLR‐9 [oligodeoxynucleotide (ODN)] directly induced cytokine production in MS patients. Among the pathogen‐associated molecular patterns (PAMPs), Pam3Csk4 was more potent than other TLR ligands in inducing the production of all proinflammatory cytokines. Furthermore, IL‐6, IFN‐γ, IL‐17 and granulocyte–macrophage colony‐stimulating factor (GM‐CSF) levels produced by Pam3Csk4‐activated CD4⁺ cells were directly associated with disease activity. A similar correlation was observed with regard to IL‐17 levels released by Pam3Csk4‐stimulated CD8⁺ T‐cells and clinical parameters. In conclusion, our data suggest that the expansion of different T helper type 17 (Th17) phenotypes expressing TLR‐2, ‐4 and ‐9 is associated with MS disease activity, and reveals a preferential ability of TLR‐2 ligand in directly inducing the production of cytokines related to brains lesions and neurological disabilities.     

C‐reactive protein levels and common polymorphisms of the interleukin‐1 gene cluster and interleukin‐6 gene in patients with coronary heart disease

C‐reactive protein (CRP) is an inflammatory marker associated with increased cardiovascular risk. Production of CRP is regulated by interleukin (IL)‐1β, IL‐1 receptor antagonist and IL‐6. In 160 patients with coronary heart disease (CHD) confirmed by angiography, we examined the relationship between CRP level and five polymorphisms in genes coding for these cytokines: IL‐1B(?511), IL‐1B(+3954), a variable number tandem repeat (VNTR) polymorphism in intron 2 of IL‐1RN [IL‐1RN(VNTR)], IL‐6(?174) and IL‐6(?572). CRP values were logarithmically normalized (log‐CRP) for statistical calculations. In univariate analysis, carrier status for the IL‐1B(+3954)T allele and IL‐1RN(VNTR) allele 2 [IL‐1RN(VNTR)*2] correlated with higher (P < 0.01) and lower (P < 0.05) log‐CRP values, respectively. Among the potential confounding factors analysed, smoking, body mass index, total cholesterol (P < 0.05 for all) and diabetes (P = 0.056) were positively correlated with CRP level. After adjustment for non‐genetic covariates, CRP levels remained significantly (P < 0.01) higher in carriers of IL‐1B(+3954)T than in non‐carriers: mean log‐CRP (with 95% confidence interval) was 0.443 (0.311–0.574) for CT or TT genotypes compared with 0.240 (0.107–0.373) for the CC genotype, which corresponded to back‐transformed CRP levels of 2.77 and 1.74 mg l^?1, respectively. Adjusted association was also significant for IL‐1RN(VNTR)*2 (P < 0.01), with lower CRP levels in the presence of allele 2: the mean log‐CRP value was 0.252 (0.115–0.388) for carriers and 0.421 (0.290–0.552) for non‐carriers (CRP 1.79 and 2.64 mg l^?1, respectively). When alleles of both polymorphisms were entered into the model simultaneously, the association remained significant for IL‐1B(+3954)T (P < 0.05), but not for IL‐1RN(VNTR)*2. We conclude that IL‐1B(+3954)T is associated with higher CRP levels in patients with CHD, and we found that this association was significant after adjustment for major risk factors. Our data also suggest a possible relationship of IL‐1RN(VNTR)*2 with lower CRP levels in the same patients.     

TLR3途径诱导多发性骨髓瘤细胞株增殖抑制和凋亡机制研究

目的 研究聚肌苷酸胞苷酸( polyI:C)激活的TLR3通路对多发性骨髓瘤RPMI8226细胞的增殖抑制和凋亡相关的生物学作用及相关机制.方法 RPMI8226细胞培养于RPMI 1640培养基,以不同浓度的polyI:C与该细胞作用不同的时间.收集细胞后,分别利用CCK-8和流式细胞术分析其增殖抑制和凋亡情况,同时抽提总RNA,相对定量PCR测定TLR3通路相关基因表达.结果 PolyI:C对RPMI8226的增殖抑制效应随着作用剂量的增加和时间的延长而增加,24h:12.30％±2.04％、22.50％±2.20％、37.90％±1.30％;48h:17.80％±1.52％、29.60±0.85％、45.80％±1.68％;72 h:25.10％±1.01％、34.60％±1.27％、60.50％±2.08％,差异有统计学意义(P＜0.05).浓度为50、100、200μg/ml的polyl:C与RPMI8226作用48 h后,细胞凋亡率分别为5.60％±1.06％、8.71％±1.06％、13.93％±1.17％,差异具有统计学意义(P＜0.05),而且随着polyI:C作用浓度增加,RPMI8226细胞中TLR3和TRIF mRNA相对于内参β-actin的表达均显著增高,TLR3:1.41±0.10、2.24±0.16、4.08±0.13;TRIF:1.07±0.16、1.97±0.13、3.56±0.19,各组间差异具有统计学意义(P＜0.05).结论 TLR3途径可以有效地抑制多发性骨髓瘤细胞增殖,并且诱导其凋亡,对多发性骨髓瘤的生物治疗具有潜在应用价值.     

cAMP对人骨髓瘤细胞的IL-6信号转导功能及细胞增殖的抑制作用

目的 研究ＰＫＡ途径激活（或胞内ｃＡＭＰ水平升高）后对人骨髓瘤细胞的ＩＬ－６信号转导功能及细胞生长的影响。方法 采用ＰＫＡ途径激动剂Ｆｏｓｋｏｌｉｎ（ＦＫ）和ｃＡＭＰ类似物８－Ｂｒ－ｃＡＭＰ刺激人骨髓瘤细胞骨－Ｓｋｏ－００７,分别通过ＭＴＴ方法和凝胶阻滞电泳（ｅｌｅｃｔｒｏｐｈｏｒｅｔｉｃ ｍｏｂｉｌｉｔｙ ｓｈｉｆｔ ａｓｓａｙ,ＥＭＳＡ）方法检测ＦＫ和８－Ｂｒ－ｃＡＭＰ对Ｓｋｏ细胞的生长及其Ｉ     

三氧化二砷对多发性骨髓瘤细胞生物学特性的影响

目的探讨三氧化二砷(As2O3)对人多发性骨髓瘤细胞系RPMI8226细胞生物学特性影响的分子机制。方法用人多发性骨髓瘤细胞系RPMI8226细胞作为体外实验对象。应用流式细胞仪检测细胞周期、凋亡峰、死亡受体DR4和DR5分子及黏附分子VLA4(CD49d)的表达;用聚合酶链反应测定靶细胞CXCR4基因表达;免疫组化染色和荧光显微镜检测DR4和DR5分子的表达情况。结果5μmol/L的As2O3可以明显上调RPMI8226细胞DR4、DR5分子的表达(P<0.01),明显下调CXCR4基因和VLA4分子表达;还可以诱导RPMI8226细胞凋亡、增加G1期细胞比例,出现明显凋亡峰。结论As2O3诱导RPMI8226细胞凋亡,可能与死亡受体DR4、DR5分子过度表达有关;As2O3抑制靶细胞CXCR4基因和黏附分子VLA4的表达,从而影响细胞的增殖、迁移与归巢能力。     

Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines

Interleukin-6 (IL-6) mediates pleiotropic functions through specific receptors (IL-6R) composed of an 80-kDa binding protein, associated with a non-ligand binding protein (gp130) which transduces the signal. Because IL-6 is the major tumor growth factor in multiple myeloma, we investigated the regulation of IL-6R in two human multiple myeloma cell lines. Binding experiments with ¹²⁵I-labeled IL-6 showed that IL-6R were expressed at a high density on RPMI-8226 cells (15 000 receptors/cell), but no specific binding was detected on XG-1 cells, whose growth depends on the presence of exogenous IL-6. However, when IL-6 was removed from the culture medium, high-affinity IL-6R appeared on the surface of XG-1 cells (5300 sites/cell). Treatment of RPMI-8226 cells with IL-6 reduced the number of IL-6R without changing their affinity. This reduction was dose dependent and was not affected by acid treatment which dissociates ligand-receptor complexes. Cross-linking experiments showed that the formation of one IL-6/receptor complex of 160 kDa markedly decreased upon IL-6 treatment, while the other complex of 190 kDa became undetectable. These data provide evidence for ligand-induced down-regulation of membrane IL-6R expression in myeloma cells. Treatment of RPMI-8226 cells with interferon-α (IFN-α), which inhibits the growth of these cells, stimulated IL-6R expression and increased the formation of the 160-kDa IL-6/receptor complex. This stimulation was specific for IFN-α, since IFN-γ reduced the number of IL-6R. These data indicate that, in myeloma cells, IL-6R are differentially regulated by IL-6 and IFN-α.     

Both PIGA and PIGL mutations cause GPI‐a deficient isolates in the Tk6 cell line

Molecular analysis of proaerolysin selected glycosylphosphatidylinositol anchor (GPI‐a) deficient isolates in the TK6 cell line was performed. Initial studies found that the expected X‐linked PIGA mutations were rare among the spontaneous isolates but did increase modestly after ethyl methane sulfate (EMS) treatment (but to only 50% of isolates). To determine the molecular bases of the remaining GPI‐a deficient isolates, real‐time analysis for all the 25 autosomal GPI‐a pathway genes was performed on the isolates without PIGA mutations, determining that PIGL mRNA was absent for many. Further analysis determined these isolates had several different homozygous deletions of the 5′ region of PIGL (17p12‐p22) extending 5′ (telomeric) through NCOR1 and some into the TTC19 gene (total deletion >250,000 bp). It was determined that the TK6 parent had a hemizygous deletion in 17p12‐p22 (275,712 bp) extending from PIGL intron 2 into TTC19 intron 7. Second hit deletions in the other allele in the GPI‐a deficient isolates led to the detected homozygous deletions. Several of the deletion breakpoints including the original first hit deletion were sequenced. As strong support for TK6 having a deletion, a number of the isolates without PIGA mutations nor homozygous PIGL deletions had point mutations in the PIGL gene. These studies show that the GPI‐a mutation studies using TK6 cell line could be a valuable assay detecting point and deletion mutations in two genes simultaneously. Environ. Mol. Mutagen. 56:663–673, 2015. © 2015 Wiley Periodicals, Inc.     

Emerging role of interleukin‐31 and interleukin‐31 receptor in pruritus in atopic dermatitis

Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, severely pruritic skin disorder associated with skin barrier dysfunction. The lesional skin of AD exhibits T helper 2 (T_H2)‐deviated immune reactions. Interleukin‐31 (IL‐31), preferentially produced from T_H2 cells, is a potent pruritogenic cytokine, and its systemic and local administration induces scratching behavior in rodents, dogs and monkeys. Recent clinical trials have revealed that administration of an anti‐IL‐31 receptor antibody significantly alleviates pruritus in patients with AD. In this review, we summarize recent topics related to IL‐31 and its receptor with special references to atopic itch.     

Clinicopathological features of plasmablastic multiple myeloma: a population‐based cohort

Multiple myeloma (MM) is a common malignant hematological disease displaying considerable heterogeneity. Historical data indicate a prognostic significance of plasmablastic morphology, proliferation, and adverse cytogenetics, but there is little knowledge on the degree of interdependency of these parameters. The aim of this study was to study the degree of overlap between these variables. In a consecutive population‐based cohort of 194 untreated MM patients, morphology, and proliferation index, using immunohistochemical double staining for Ki‐67 and CD138, was analyzed. In addition, cytogenetic changes were studied by karyotyping and fluorescence in situ hybridization (FISH). Plasmablastic morphology correlated with unfavorable clinical features, high proliferation index, high percentage of plasma cell infiltration in the bone marrow, abnormal karyotype, and del(13q) detected by karyotyping, which indicates that plasmablastic morphology reflects advanced and highly proliferative disease. However, plasmablastic morphology did not correlate with established adverse prognostic cytogenetics identified by FISH, for example, t(4;14), t(14;16) and del(17p).     

Distinct sustained structural and functional effects of interleukin‐33 and interleukin‐25 on the airways in a murine asthma surrogate

Interleukin‐25 (IL‐25) and IL‐33, which belong to distinct cytokine families, induce and promote T helper type 2 airway inflammation. Both cytokines probably play a role in asthma, but there is a lack of direct evidence to clarify distinctions between their functions and how they might contribute to distinct ‘endotypes’ of disease. To address this, we made a direct comparison of the effects of IL‐25 and IL‐33 on airway inflammation and physiology in our established murine asthma surrogate, which involves per‐nasal, direct airway challenge. Intranasal challenge with IL‐33 or IL‐25 induced inflammatory cellular infiltration, collagen deposition, airway smooth muscle hypertrophy, angiogenesis and airway hyper‐responsiveness, but neither increased systemic production of IgE or IgG1. Compared with that of IL‐25, the IL‐33‐induced response was characterized by more sustained laying down of extracellular matrix protein, neoangiogenesis, T helper type 2 cytokine expression and elevation of tissue damping. Hence, both IL‐25 and IL‐33 may contribute significantly and independently to asthma ‘endotypes’ when considering molecular targets for the treatment of human disease.     

Synergistic effect of interleukin‐17 and tumour necrosis factor‐α on inflammatory response in hepatocytes through interleukin‐6‐dependent and independent pathways

The proinflammatory cytokines interleukin (IL)‐17 and tumour necrosis factor (TNF)‐α are targets for treatment in many chronic inflammatory diseases. Here, we examined their role in liver inflammatory response compared to that of IL‐6. Human hepatoma cells (HepaRG, Huh7.5 and HepG2 cells) and primary human hepatocytes (PHH) were cultured with IL‐6, IL‐17 and/or TNF‐α. To determine the contribution of the IL‐6 pathway in the IL‐17/TNF‐α‐mediated effect, an anti‐IL‐6 receptor antibody was used. IL‐17 and TNF‐α increased in synergy IL‐6 secretion by HepaRG cells and PHH but not by Huh7.5 and HepG2 cells. This IL‐17/TNF‐α synergistic cooperation enhanced the levels of C‐reactive protein (CRP) and aspartate aminotransferase (ASAT) in HepaRG cell and PHH cultures through the induction of IL‐6. IL‐17/TNF‐α also up‐regulated IL‐8, monocyte chemoattractant protein (MCP)‐1 and chemokine (C‐C motif) ligand 20 (CCL20) chemokines in synergy through an IL‐6‐independent pathway. Interestingly, first exposure to IL‐17, but not to TNF‐α, was crucial for the initiation of the IL‐17/TNF‐α synergistic effect on IL‐6 and IL‐8 production. In HepaRG cells, IL‐17 enhanced IL‐6 mRNA stability resulting in increased IL‐6 protein levels. The IL‐17A/TNF‐α synergistic effect on IL‐6 and IL‐8 induction was mediated through the activation of extracellular signal‐regulated kinase (ERK)‐mitogen‐activated protein kinase, nuclear factor‐κB and/or protein kinase B (Akt)–phosphatidylinositol 3‐kinase signalling pathways. Therefore, the IL‐17/TNF‐α synergistic interaction mediates systemic inflammation and cell damage in hepatocytes mainly through IL‐6 for CRP and ASAT induction. Independently of IL‐6, the IL‐17A/TNF‐α combination may also induce immune cell recruitment by chemokine up‐regulation. IL‐17 and/or TNF‐α neutralization can be a promising therapeutic strategy to control both systemic inflammation and liver cell attraction.     

Genetic association of interleukin‐2, interleukin‐4, interleukin‐6, transforming growth factor‐β, tumour necrosis factor‐α and blood concentrations of calcineurin inhibitors in Turkish renal transplant patients

Cytokines are essential for the control of the immune response as most of the immunosuppressive drugs target cytokine production or their action. The calcineurin inhibitors (CNIs) cyclosporine (CsA) and tacrolimus are immunosuppressive drugs widely used after renal transplantation to prevent allograft rejection. They are characterized by large interindividual variability in their pharmacokinetics; therefore, monitoring their blood concentrations is important to predict their optimal dosage following transplantation. Calcineurin inhibitors inhibit the phosphatase activity of calcineurin, thereby suppressing the production of other cytokines such as transforming growth factor (TGF‐β), tumour necrosis factor‐α (TNF‐α), interleukin (IL)‐6, IL‐2, and IL‐4. The aim of this study was to investigate the relationship between polymorphisms of cytokines and blood concentrations of CNIs in renal transplant patients. The study included 53 CsA‐treated renal transplant patients and 37 tacrolimus‐treated renal transplant patients. Cytokine polymorphisms were analysed using polymerase chain reaction (PCR) sequence‐specific primers with the cytokine CTS‐PCR‐sequence‐specific primers Tray Kit; University of Heidelberg. Blood concentrations of CNIs were determined with Cloned Enzyme Donor Immunoassay (CEDIA) method. Patients with TC genotype of TGF‐β at codon 10 had lower CsA blood concentrations than the TT and CC genotypes (P = 0.005) at 1 month in CsA treatment group. The ratio of blood concentration/dose of CsA for patients with TGF‐β1‐codon 10 TC genotype was lower than for patients with TT, CC genotypes, and the dose given to these patients was higher in the first month (P = 0.046). The ratio of blood concentration/dose of CsA for patients with IL‐2‐330 GG genotype was higher than for patients with GT, TT genotypes, and the dose given to these patients was lower at first month and sixth months (P = 0.043, P = 0.035 respectively). The tacrolimus blood concentrations were significantly higher in patients with the genotype GG of IL‐2‐330 (P = 0.012) at the third month. Patients who had the TC genotype TGF‐β codon 10 had lower CsA blood concentrations and this group had higher acute rejection (P = 0.033). These results suggest that the genotyping for TGF‐β‐codon 10, IL‐2‐330 and IL‐6‐174 polymorphisms may help individualized immunosuppressive dosage regiments.     

Bone marrow type 2 innate lymphoid cells: a local source of interleukin‐5 in interleukin‐33‐driven eosinophilia

T helper type 2 (Th2) cells, type 2 innate lymphoid cells (ILC2s) and eosinophil progenitors have previously been described to produce interleukin‐5 (IL‐5) in the airways upon allergen provocation or by direct administration of IL‐33. Eosinophilic airway inflammation is known to be associated with IL‐5‐dependent eosinophil development in the bone marrow, however, the source of IL‐5 remains unclear. T helper cells, ILC2s and CD34⁺ progenitors have been proposed to be involved in this process, therefore, we investigated whether these cells are taking part in eosinophilopoiesis by producing IL‐5 locally in the bone marrow in IL‐33‐driven inflammation. Airway exposure with IL‐33 led to eosinophil infiltration in airways and elevated eotaxin‐2/CCL24. Importantly, IL‐5 production as well as expression of the IL‐33 receptor increased in ILC2s in the bone marrow under this treatment. A small but significant induction of IL‐5 was also found in CD34⁺ progenitors but not in T helper cells. Similar results were obtained by in vitro stimulation with IL‐33 where ILC2s rapidly produced large amounts of IL‐5, which coincided with the induction of eosinophil hematopoiesis. IL‐33‐mediated eosinophil production was indeed dependent on IL‐5 as both airway and bone marrow eosinophils decreased in mice treated with anti‐IL‐5 in combination with IL‐33. Interestingly, the responsiveness of ILC2s to IL‐33 as well as IL‐33‐induced eotaxin‐2/CCL24 were independent of the levels of IL‐5. In summary, we demonstrate for the first time that IL‐33 acts directly on bone marrow ILC2s, making them an early source of IL‐5 and part of a process that is central in IL‐33‐driven eosinophilia.     

Rab1A对多发性骨髓瘤细胞系8226增殖和凋亡的影响

目的 探讨Rab1A对多发性骨髓瘤(MM)细胞系8226增殖和凋亡的影响.方法 采用siRNA干扰RabIA表达,将多发性骨髓瘤细胞8226分为空白对照组、阴性对照组和Rab1A siRNA组.其中空白对照组的多发性骨髓瘤细胞8226不做任何处理,阴性对照组的多发性骨髓瘤细胞8226转染阴性对照siRNA.Rab1A ...